Home Compare AMGN vs JNJ
Stock Comparison · Industry comparison · Drug Manufacturers - General

Amgen vs Johnson & Johnson: Which Stock Looks Stronger in 2026?

Johnson & Johnson holds the cleaner structural position, with stability as the main driver and profitability adding further support. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in stability, but profitability adds another real layer to the result. Johnson & Johnson leads by 10 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. AMGN and JNJ share the same industry classification.

For a similarity-based comparison, see how Amgen and Johnson & Johnson each position within their functional peer groups in AssetNext.

Peer-Relative Score
AMGN
Amgen Inc.
63
Peer-Score
Signal qualityHigh
vs
JNJ
Johnson & Johnson
73
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: AMGN vs JNJ Profitability 50 69 Stability 57 86 Valuation 73 69 Growth 75 69 AMGN JNJ
Gap Ranking
#1 Stability +29
#2 Profitability +19
#3 Growth +6
#4 Valuation +4
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AMGN and JNJ Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AMGNJNJ Relative valuation Structural strength

Neither company combines the stronger profile with the cheaper valuation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Stability
Both rank well on stability, but Johnson & Johnson still holds a clear edge.
Profitability
On profitability, the edge still sits with Johnson & Johnson, even though both profiles look solid.
Stability — Dominant Gap
AMGN
57
JNJ
86
Gap+29in favour of JNJ

The clearest distance comes from a steadier profile over time.

What keeps the gap from being one-sided

Amgen Inc. still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.

What this means for the comparison

Stability is the clearest driver, and profitability also supports Johnson & Johnson's broader structural position.

Explore full peer positioning in AssetNext

Break down the AMGN vs JNJ comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar stability-and-profitability comparisons

Explore how AMGN and JNJ each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.